Enzymatica AB (publ) (STO:ENZY)

Market Cap	720.92M
Revenue (ttm)	48.43M
Net Income (ttm)	-52.32M
Shares Out	242.74M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,068
Average Volume	69,848
Open	3.000
Previous Close	2.990
Day's Range	2.940 - 3.080
52-Week Range	1.340 - 5.450
Beta	0.21
RSI	40.35
Earnings Date	Jul 17, 2025

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.